Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274451 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate LYL797 in Adults With Solid Tumors
A Phase 1 study, sponsored by Lyell Immunopharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT05274451 is a Phase 1 study that was terminated before completion, run by Lyell Immunopharma. The registered enrollment target is 57 participants.
The verdict
NCT05274451, a Phase 1 study, was terminated before completion, sponsored by Lyell Immunopharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer (Ovarian cancer), or Endometrial cancer. The first part of the study will determine the safe dose for the next part of the study, and will enroll patients with TNBC, NSCLC, Ovarian or Endometrial cancer. The second part of the study will test that dose in additional patients with TNBC, NSCLC, Ovarian or Endometrial cancer.
Interventions
- BIOLOGICAL LYL797
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2024-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05274451
The ClinicalTrials.gov registry entry for NCT05274451 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lyell Immunopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LYL797 is the first listed.
NCT05274451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05274451 about?
NCT05274451 is a clinical study titled "A Study to Investigate LYL797 in Adults With Solid Tumors". This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary per...
What is the current status of trial NCT05274451?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2022-03-29. Estimated completion is 2024-11-27.
What interventions are being tested in trial NCT05274451?
The interventions under investigation include: LYL797 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05274451?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.